Literature DB >> 19104409

The impact of purinergic signaling on renal ischemia-reperfusion injury.

Bo Lu1, Siddharth V Rajakumar, Simon C Robson, Eddy K F Lee, Sandra Crikis, Anthony J F d'Apice, Peter J Cowan, Karen M Dwyer.   

Abstract

BACKGROUND: Adenosine provides renovascular protection in mouse models of ischemia-reperfusion injury (I/RI) through purinergic members of the G protein-coupled receptor family, such as the adenosine 2A receptor (A2AR). Ectonucleotidases CD39 and CD73 are integral vascular and immune nucleotidases that regulate extracellular adenosine signaling. Current investigation of CD39 and CD73 in renal I/RI has primarily focused on their respective roles in ischemic preconditioning.
METHODS: In this study, we established a unilateral renal I/RI model and investigated the role of adenosine generation versus nucleotide removal in mediating protection in renal I/RI using mice deficient in CD39, CD73 or A2AR, thereby sequentially disrupting ectonucleotidase cascade and adenosinergic signaling.
RESULTS: Compared with wild-type mice, Cd73 null mice showed reduced levels of serum creatinine and urea, apoptosis of renal cells, and histologic damage after I/RI. Deletion of CD39 was associated with severe renal injury. Administration of apyrase, a soluble form of CD39, decreased global apoptosis and I/RI induced renal injury in wild-type mice. Apyrase treatment also improved renal histology to some extent in A2AR null mice.
CONCLUSION: The relative protective effect of CD73 deletion in renal I/RI may reflect an effect of AMP accumulation. Deletion of CD39 showed deleterious effects and administration of soluble CD39 exerted renal protection, which is partially mediated by A2AR. The protective effect conferred by apyrase suggests that supplementing CD39 NTPDase activity may be a useful therapeutic strategy in renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104409     DOI: 10.1097/TP.0b013e31819022bc

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  24 in total

Review 1.  The 2',3'-cAMP-adenosine pathway.

Authors:  Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

2.  A2B adenosine receptor-mediated induction of IL-6 promotes CKD.

Authors:  Yingbo Dai; Weiru Zhang; Jiaming Wen; Yujin Zhang; Rodney E Kellems; Yang Xia
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 3.  Molecular mechanisms of ischemic preconditioning in the kidney.

Authors:  Pinelopi P Kapitsinou; Volker H Haase
Journal:  Am J Physiol Renal Physiol       Date:  2015-08-26

Review 4.  Biological implications of extracellular adenosine in hepatic ischemia and reperfusion injury.

Authors:  M A Zimmerman; I Kam; H Eltzschig; A Grenz
Journal:  Am J Transplant       Date:  2013-08-07       Impact factor: 8.086

Review 5.  Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.

Authors:  Karen M Dwyer; Bellamkonda K Kishore; Simon C Robson
Journal:  Nat Rev Nephrol       Date:  2020-07-08       Impact factor: 28.314

Review 6.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

7.  Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.

Authors:  Maithili Sashindranath; Karen M Dwyer; Shala Dezfouli; Carly Selan; Sandra Crikis; Bo Lu; Yuping Yuan; Michael J Hickey; Karlheinz Peter; Simon C Robson; Peter J Cowan; Harshal H Nandurkar
Journal:  Purinergic Signal       Date:  2017-03-25       Impact factor: 3.765

Review 8.  Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.

Authors:  Rebecca A Torres; William Lewis
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

9.  Attenuated allergic airway inflammation in Cd39 null mice.

Authors:  M Idzko; C K Ayata; T Müller; T Dürk; M Grimm; K Baudiß; R P Vieira; S Cicko; C Boehlke; A Zech; S Sorichter; J Pelletier; J Sévigny; S C Robson
Journal:  Allergy       Date:  2013-03-01       Impact factor: 13.146

10.  Extracellular 2',3'-cAMP-adenosine pathway in proximal tubular, thick ascending limb, and collecting duct epithelial cells.

Authors:  Edwin K Jackson; Delbert G Gillespie
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.